ReviewWorld journal of gastroenterology2013
How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?
Review in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Tailored therapy forFrontiers in pharmacology · 2022Pooled it
- Probiotic monotherapy andWorld journal of gastroenterology · 2018Pooled it
- New fecal test for non-invasiveWorld journal of gastroenterology · 2018Trial
- Resistance to Clarithromycin and Fluoroquinolones inAntibiotics (Basel, Switzerland) · 2025Article
- Antibiotic Resistance Identification Among the Patients withMiddle East journal of digestive diseases · 2025Article
- Review of Methods for DetectionJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Efficacy and safety of Jinghua Weikang capsule combined with amoxicillin-furazolidone triple/quadruple therapies in the rescue treatment ofFrontiers in medicine · 2025Article
- Experience of Metronidazole Triple Therapy After Clarithromycin Triple Therapy Failure forJournal of clinical medicine · 2024Article
- Review
- Role of MIC levels and 23S rRNA mutation sites to clarithromycin in 14-day clarithromycin bismuth quadruple therapy forHeliyon · 2024Article
- The Anti-Helicobacter pylori effects of Limosilactobacillus reuteri strain 2892 isolated from Camel milk in C57BL/6 mice.World journal of microbiology & biotechnology · 2023Article
- The State of the Art of Molecular Fecal Investigations forInternational journal of molecular sciences · 2023Review
- Review
- Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-LineAntibiotics (Basel, Switzerland) · 2022Article
- The efficacy and safety of furazolidone-bismuth quadruple therapy forGastroenterology and hepatology from bed to bench · 2022Article
- Second-Line Bismuth-Containing Quadruple Therapy forJournal of clinical medicine · 2021Article
- Two-weeks repeated-dose oral toxicity study of Pediococcus acidilactici J9 in a mice model.BMC microbiology · 2020Article
- Article
- Age and gender-specific antibiotic resistance patterns among Bangladeshi patients with urinary tract infection caused byHeliyon · 2020Article
- The Puzzle of Coccoid Forms ofAntibiotics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic management of Helicobacter pylori (H. pylori) remains an unsolved issue. Indeed, no therapeutic regimen is able to cure the infection in all treated patients, and in many the infection persists despite the administration of several consecutive standard therapies. Although antibiotic resistance reports describe alarming results, the outcome of therapeutic regimens does not seem to parallel this scenario in most cases, since a successful performance is often reached in more than 80% of cases. However, the phenomenon of increasing antibiotic resistance is being closely studied, and the results show controversial aspects even in the same geographic area. For the continents of Europe, America, Asia, Africa, and Oceania, minimal and maximal values of resistance to the main antibiotics (clarithromycin, amoxicillin, metronidazole, and levofloxacin) feature wide ranges in different countries. The real enigma is therefore linked to the several different therapeutic regimens, which show results that often do not parallel the in vitro findings even in the same areas. A first aspect to be emphasized is that some regimens are limited by their use in very small geographic districts. Moreover, not all therapeutic trials have considered bacterial and host factors affecting the therapeutic outcome. The additional use of probiotics may help to reduce adverse events, but their therapeutic impact is doubtful. In conclusion, the "ideal therapy", paradoxically, appears to be a "utopia", despite the unprecedented volume of studies in the field and the real breakthrough in medical practice made by the discovery and treatment of H. pylori. The ample discrepancies observed in the different areas do not encourage the development of therapeutic guidelines that could be valid worldwide. On these bases, one of the main challenges for the future might be identifying a successful solution to overcome antibiotic resistances. In this context, geography must be considered a relevant matter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.